Latest market price
9.13
-0.60-6.17%
OverviewShort InterestFilings
BCAXQT9Bicara Therapeutics Inc. Common Stock·NASDAQ
9.13-6.17%
TA
Loading chart...
Signal & projected range
Gap down — mean-reversionHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
TRAX-0.33%$45.08NVAX-3.72%$10.08NUVB-0.21%$4.76KLRA-4.10%$12.86REPL+1.27%$17.61STOK-0.23%$26.29QURE-1.86%$24.83NTLA-5.74%$12.47
Snapshot
Index—P/E—EPS (ttm)-3.10Insider Own30.51%Shs Outstand66.17MPerf Week-46.51%
Market Cap604.16MForward P/E—EPS next Y-3.62Insider Trans-0.80%Shs Float36.90MPerf Month-49.84%
Enterprise Value108.16MPEG—EPS next Q-0.84Short Float27.91%Perf Quarter-64.53%
Income-184.00MP/S—EPS this Y—Short Ratio15.54Perf Half Y-57.87%
Sales0.00P/B1.29EPS next Y—ROA-36.19%Short Interest10.30MPerf YTD-45.75%
Book/sh7.09P/C1.22EPS next 5Y—ROE-41.49%52W High30.99 -70.54%Perf Year-42.51%
Cash/sh7.51P/FCF—EPS past 3/5Y—ROIC-42.98%52W Low8.36 9.21%Perf 3Y—
Dividend Est.—EV/EBITDA—Sales past 3/5Y—Gross Margin0.00%Volatility16.35% 8.47%Perf 5Y—
Dividend TTM—EV/Sales—EPS Y/Y TTM—Oper. Margin0.00%ATR (14)1.53Perf 10Y—
Dividend Ex-Date—Quick Ratio11.59Sales Y/Y TTM—Profit Margin0.00%RSI (14)17.49Recom2.33
Dividend Gr. 3/5Y—Current Ratio11.59EPS Q/Q-64.00%SMA20-43.44%Beta0.91Target Price31.57
Payout0.00%Debt/Eq0.00Sales Q/Q—SMA50-53.75%Rel Volume4.04Prev Close9.73
Employees103LT Debt/Eq0.00EarningsNov 09SMA200-56.95%Avg Volume1.04MPrice9.13
IPO DateSep 13, 2024Option/ShortYes / YesEPS/Sales Surpr.-0.03% —Net Debt/EBITDA—Volume4,195,036Change-6.17%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-29-26ReiteratedWedbushOutperform$33 → $24
Oct-20-26ReiteratedMorgan StanleyOverweight$39 → $41
Aug-18-26InitiatedBMO CapitalOutperform$35
Aug-12-26ReiteratedGoldman SachsNeutral$18 → $20
Aug-12-26ReiteratedWedbushOutperform$33
Aug-12-26ReiteratedMizuhoNeutral$18 → $20
Aug-12-26ReiteratedBTIGBuy$28 → $39
May-12-26ReiteratedMorgan StanleyOverweight$35 → $37
May-12-26ReiteratedGoldman SachsNeutral$14 → $18
May-11-26InitiatedGuggenheimBuy$42
Latest News· Times ET
Oct-28-26
Oct-28-2604:00PM
Top US Stock Movers in Today's SessionChartMill
Oct-19-26
Oct-19-2608:07AM
Bicara Therapeutics (NASDAQ:BCAX) Given Buy Rating at BTIG Researchdefenseworld.net
01:56AM
BTIG Reiterates Buy on Bicara Therapeutics, Maintains $39 Price TargetBenzinga
Oct-10-26
Oct-10-2606:09AM
Bicara Therapeutics (BCAX) Stock May Look Overvalued On Book ValueYahoo
Oct-05-26
Oct-05-2608:30AM
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)globenewswire.com
Sep-03-26
Sep-03-2608:30AM
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)globenewswire.com
Aug-19-26
Aug-19-2601:56AM
BMO Capital Initiates Coverage On Bicara Therapeutics with Outperform Rating, Announces Price Target of $35Benzinga
Aug-14-26
Aug-14-2608:30AM
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)globenewswire.com
03:37AM
Dimensional Fund Advisors LP Increases Stock Position in Bicara Therapeutics Inc. $BCAXdefenseworld.net
Aug-12-26
Aug-12-2611:11AM
Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwindsseekingalpha.com
10:23AM
Goldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20Benzinga
08:34AM
Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Resultsbenzinga.com
Aug-11-26
Aug-11-2611:57AM
Bicara Therapeutics Inc. (BCAX) Q2 2026 Earnings Call Transcriptseekingalpha.com
10:06AM
Bicara Therapeutics Q2 Earnings Call Highlightsmarketbeat.com
Aug-04-26
Aug-04-2608:30AM
Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ETglobenewswire.com
Company

Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
Total Revenue
0000—
Cost of Goods Sold Incl. D&A
0000—
Gross Profit
0000—
Selling, General and Administrative Excl. Other4331199—
Research and Development1331256431—
Other Operating Expense260-10—
Operating Income-202-156-82-40—
Interest Expense
0000—
Unusual Expense
—————
Non-Operating Income (Expense)171815-12—
Net Income Before Taxes-184-138-68-52—
Income Taxes
0000—
Consolidated Net Income-184-138-68-52—
Net Income From Continuing Operations-184-138-68-52—
Net Income-184-138-68-52—
EPS (Recurring)-3.10-2.52-1.25-1.00—
EPS (Basic, Before Extraordinaries)-3.10-2.52-1.25-1.00—
EPS (Diluted)-3.10-2.52-1.25-1.00—
EBITDA-184-138-68-52—
Other After Tax Adjustments
—————
Stock Option Compensation Expense
—————
Price To Earnings Ratio
—————
Price To Sales Ratio
—————
Gross Margin
—————
Operating Margin
—————
Net Margin
—————
Shares Outstanding68555452—
Market Capitalization621926941——
Operating Lease Expense
—————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$33.59$26.68$19.77$12.85$5.94● Close Price0.00M1.20M2.40M3.60M4.80MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Cohlhepp RyanPresident, COO & Interim CEOSep 08 '26Sale22.9017,500400,716181,641Sep 10
Cohlhepp RyanPresident, COO & Interim CEOSep 08 '26Option Exercise3.7917,50066,322199,141Sep 10
Hyep IvanChief Financial OfficerAug 10 '26Sale27.9712,500349,591129,855Aug 12
Mazumdar ClaireChief Executive OfficerAug 10 '26Option Exercise3.7910,00037,898372,152Aug 12
Mazumdar ClaireChief Executive OfficerAug 10 '26Sale27.9810,000279,750362,152Aug 12
Cohlhepp RyanPresident and COOAug 10 '26Option Exercise3.7918,75071,059200,391Aug 12
Cohlhepp RyanPresident and COOAug 10 '26Sale27.9818,750524,533181,641Aug 12
Hyep IvanChief Financial OfficerAug 10 '26Option Exercise3.7912,50047,373142,355Aug 12
Mazumdar ClaireChief Executive OfficerJul 10 '26Sale28.4210,000284,198362,152Jul 14
Mazumdar ClaireChief Executive OfficerJul 10 '26Option Exercise3.7910,00037,898372,152Jul 14
Cohlhepp RyanPresident and COOJul 09 '26Sale29.0053615,544181,641Jul 10
Cohlhepp RyanPresident and COOJul 08 '26Sale28.9828,214817,586182,177Jul 10
Cohlhepp RyanPresident and COOJul 08 '26Option Exercise3.7918,75071,059210,391Jul 10
Hyep IvanChief Financial OfficerJul 08 '26Option Exercise3.7925,00094,745157,855Jul 10
Hyep IvanChief Financial OfficerJul 08 '26Sale28.8528,000807,672129,855Jul 10
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.